The company released a trading update for the full year to 30 June 2022. Revenues are reported to be £72.8m (FC £75.8m). Despite this, the net loss is expected to be broadly in line with market consensus, helped by lower R&D expenses and tight control over operating expenses. Cash at 30 June was £20.5m (FC £24.5m), partly due to R&D pre-payments as well as lower revenues. Both the pivotal Phase III Grass MATAMPL trial and Phase I VLP Peanut allergy vaccine remain on track to start recruitment in ....
